Ontology highlight
ABSTRACT: Background
Innovative therapies have improved the overall survival in melanoma, although a high number of patients still experience disease progression or recurrence. Ex-vivo culture of circulating tumour cells (CTCs) represents a valuable laboratory resource for in-depth characterization of rare cell populations responsible for disease progression.Methods
CTCs from patients with metastatic melanoma were in-vitro established. Their stemness was demonstrated by both phenotypic and genotypic assays, as well as by functional studies. Xenograft experiments in NOD.CB17 mice injected with CTCs from a single patient were completed. Data were analysed by Student's test and results expressed as mean ± SEM.Results
CTCs share the mutational profile with primary cells, an intermediate epithelial-mesenchymal transition (EMT) phenotype and high expression of the immunosuppressive factors. A subclonal CTC population exhibited stem cell properties as high aldehyde dehydrogenase 1 activity, melanosphere-forming ability, and expression of major stemness transcription factors. Xenograft experiments confirmed the CTC ability to generate melanoma in-vivo and revealed enhanced metastatic propensity.Conclusions
CTCs play a relevant role in melanoma and may actively contribute to drive the disease progression and metastasis. Thus, they are a unique potential tool for pharmacogenomic studies to guide treatment strategies in advanced disease.
SUBMITTER: Felici C
PROVIDER: S-EPMC9275157 | biostudies-literature | 2022 Jul
REPOSITORIES: biostudies-literature
Felici Claudia C Mannavola Francesco F Stucci Luigia Stefania LS Duda Loren L Cafforio Paola P Porta Camillo C Tucci Marco M
BMC cancer 20220711 1
<h4>Background</h4>Innovative therapies have improved the overall survival in melanoma, although a high number of patients still experience disease progression or recurrence. Ex-vivo culture of circulating tumour cells (CTCs) represents a valuable laboratory resource for in-depth characterization of rare cell populations responsible for disease progression.<h4>Methods</h4>CTCs from patients with metastatic melanoma were in-vitro established. Their stemness was demonstrated by both phenotypic and ...[more]